

Note

Incorporating Morpholine and Oxetane into Benzimidazolequinone Anti-Tumour Agents: The Discovery of 1,4,6,9-Tetramethoxyphenazine from Hydrogen Peroxide and Hydroiodic Acid-Mediated Oxidative Cyclizations

Darren Conboy, Styliana I. Mirallai, Austin Craig, Patrick McArdle,
Ali A. Al-Kinani, Stephen J. Barton, and Fawaz Aldabbagh

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b01427 • Publication Date (Web): 11 Jul 2019

Downloaded from pubs.acs.org on July 11, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Incorporating Morpholine and Oxetane into Benzimidazolequinone Anti-Tumour Agents: The Discovery of 1,4,6,9-Tetramethoxyphenazine from Hydrogen Peroxide and Hydroiodic Acid-Mediated Oxidative Cyclizations

Darren Conboy,[†] Styliana I. Mirallai,[‡] Austin Craig,[‡] Patrick McArdle,[‡] Ali A. Al-Kinani,[†] Stephen Barton,[†] and Fawaz Aldabbagh^{*†,‡,§}

[†]Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, Penrhyn Road, Kingston upon Thames, KT1 2EE, UK.

[‡]School of Chemistry, National University of Ireland Galway, University Road, Galway, H91 TK33, Ireland.

ABSTRACT: The reactivity of hydrogen peroxide and catalytic hydroiodic acid towards 3,6-dimethoxy-2-(cycloamino)anilines is tunable to give ring-fused benzimidazoles or 1,4,6,9-tetramethoxyphenazine in high yield. Mechanisms via a detected nitroso-intermediate are proposed for oxidative cyclization and the unexpected intermolecular displacement of the oxazine. An aqueous solution of molecular iodine is capable of the same transformations. Oxidative demethylation gave targeted benzimidazolequinones, including without cleavage of the incorporated oxetane.

Morpholine is prevalent in marketed drugs.¹ The replacement of functional groups with morpholine can increase metabolic stability and hydrophilicity.^{2,3} Oxetane is a cyclic ether with similar hydrogen bonding avidity to morpholine, which has emerged as a polar alternative to the *gem*-dimethyl group in medicinal chemistry.^{4,5} NAD(P)H:quinone oxidoreductase 1 (NQO1) is a reductase over-expressed in many solid tumours.^{6,7} Benzimidazolequinones are reported excellent substrates for NQO1, which was demonstrated using recombinant human NQO1.⁸ Computational docking has shown that a polar group (e.g. cyclic ether) four or five bonds away from the quinone functional group can lead to more efficient NQO1 binding.⁹ This led us to target morpholine and spirocyclic oxetane ring-fused benzimidazolequinones **1** and **2** (Figure 1).





Figure 1. Synthetic targets.

Hydrogen peroxide is a cheap, low molar mass, odorless, and eco-friendly oxidant with high atom economy. H_2O_2 is an established mediator for the oxidative cyclization of *o*-cyclic amine substituted anilines to give ring-fused benzimidazoles.¹⁰⁻¹⁵ We have shown that when H_2O_2 is combined with HX (where X = Cl or Br), the oxidative cyclization can be accompanied by a selective aromatic halogenation in one-pot.¹³ When the same H_2O_2 and HX system was applied to 3,6-dimethoxy-2-


(cycloamino)anilines, a tunable one-pot transformation was established (Scheme 1(b)).¹⁵

Scheme 1. H_2O_2 and HX-Mediated Transformations.


(a) The combination of H_2O_2 and HX:



(b) Previous work (X = Cl, Br):¹⁵



(c) This work:




A higher molar ratio of H_2O_2 relative to HX resulted in halogenation and oxidative cyclization, while lower relative

amounts of H₂O₂ to HX mediated one-pot halogenation, cyclization and quinone formation, generating halogenated ring-fused benzimidazolequinones. A larger proportion of the hydrohalic acid relative to hydrogen peroxide favors halogen (X₂) formation (Scheme 1(a)), and molecular chlorine and bromine in water were shown to independently mediate the six-electron oxidative transformation to give the halogenated ring-fused benzimidazolequinones. The use of hydroiodic acid (HI) is preferred over the other hydrohalic acids for the synthesis of targets **1** and **2**, since the oxidative cyclization is more likely to occur without halogenation, as the electrophilicity of the halogens decreases from Cl₂>Br₂>I₂.¹⁶ Herein, the reactivity of 3,6-dimethoxy-2-(cycloamino)anilines using H₂O₂ and a catalytic amount of HI in ethyl acetate is shown to be tunable to favor either the intramolecular reaction to give ring-fused benzimidazoles or the unexpected intermolecular reaction to give 1,4,6,9-tetramethoxyphenazine (Scheme 1 (c)).

The four-step synthesis of ring-fused benzimidazolequinones **1** and **2** began with nucleophilic aromatic substitution (S_NAr) of morpholine and 2-oxa-7-azaspiro[3.5]nonane¹⁷ onto 1,4-dimethoxy-2,3-dinitrobenzene. The substitution using bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate gave 7-(3,6-dimethoxy-2-nitrophenyl)-2-oxa-7-azaspiro[3.5]nonane (**3**) in 68% yield, when using K₂CO₃ (4 equiv) in a 5:1 acetonitrile:water mixture (Scheme 2). Reduction of nitrobenzenes with iron powder gave the aniline oxidative cyclization precursors in high yields with 3,6-dimethoxy-2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (**4b**) formed in 80% yield.

Scheme 2. Preparation of 3,6-Dimethoxy-2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (**4b**).




With 3,6-dimethoxy-2-(morpholin-4-yl)aniline (**4a**)¹⁵ and spirocyclic oxetane analogue **4b** in hand, the oxidative cyclization using H₂O₂ and HI was investigated (Table 1). In keeping with the principles of green chemistry, ethyl acetate was chosen as the reaction solvent.^{14,18} Morpholine **4a** did not undergo any transformation in EtOAc at reflux in the presence of H₂O₂ (20 equiv) alone. Addition of one stoichiometric equivalent of HI gave after 1 hour, 6,9-dimethoxy-3,4-dihydro-1*H*-[1,4]oxazino[4,3-*a*]benzimidazole (**5a**) in 56% yield along with an unexpected orange precipitate. Spectroscopic data identified the precipitate as 1,4,6,9-tetramethoxyphenazine (**6**), formed in 25% yield. Using less than stoichiometric amounts of HI (0.2 equiv), increased the yield of the desired benzimidazole **5a** to 69%, and less phenazine **6** formed in

19% yield. Using these conditions on substrate **4b** gave spirocyclic oxetane ring-fused benzimidazole **5b** in 74% yield with 11% phenazine **6** formed. The amount of phenazine **6** (12% yield) was consistent for other six-membered cyclizations, as demonstrated by conversion of 3,6-dimethoxy-2-(piperidin-1-yl)aniline (**4c**) to give 6,9-dimethoxy-1,2,3,4-tetrahydropyrido[1,2-*a*]benzimidazole (**5c**) in 72% yield. Variation of ring-sizes was investigated, with the five- and seven-membered cyclizations of 3,6-dimethoxy-(2-pyrrolidin-1-yl)aniline (**4d**) and 2-(azepan-1-yl)-3,6-dimethoxyaniline (**4e**) proceeding in high yield to respectively give 5,8-dimethoxy-2,3-dihydro-1*H*-pyrrolo[1,2-*a*]benzimidazole (**5d**) and 1,4-dimethoxy-7,8,9,10-tetrahydro-6*H*-azepino[1,2-*a*]benzimidazole (**5e**) in 89% and 91% yield. The absence of phenazine **6** from the latter reactions is consistent with previous observations of six-membered oxidative cyclizations being more difficult than those forming five and expanded ring-fused benzimidazole analogues.¹⁴ For all reactions, chromatography was not required, with residues triturated in diethyl ether to afford benzimidazoles **5a-5e**.


Phenazine is the scaffold of secondary metabolites from *Pseudomonas* and *Streptomyces* with many natural and unnatural examples having potent biological activity, notably anti-cancer.^{19,20} The oldest synthesis is the Wohl-Aue reaction,²¹ which is known to be low-yielding, and reported to give 1,4,6,9-tetramethoxyphenazine (**6**) in 10% yield using potassium hydroxide in benzene (Scheme 3).²² We attempted to improve this condensation of the aniline with nitrobenzene by using potassium *tert*-butoxide as base in toluene,²³ but the yield of **6** remained low, at 34%. We set about establishing a more facile route to **6** through manipulation of the optimized H₂O₂ and HI-mediated oxidative cyclization conditions for morpholine **4a** (Table 1). Given that phenazine **6** formation is an intermolecular reaction, it seemed plausible that the use of more concentrated conditions (less ethyl acetate) would lead to increased yields of **6**. This was indeed the case when reducing the amount of solvent by 4-fold, phenazine **6** became the major product in 47% yield with benzimidazole **5a** formed in 28% yield. The H₂O₂ and HI-mediated cyclization seemed to give the thermodynamic product, since the yield of cyclized benzimidazole **5a** became increasingly insignificant (4% then 2%), when reducing the reaction temperature from reflux to 40 °C to room temperature with phenazine **6** isolated in excellent yield of 82%. The requirement for higher temperatures for the cyclization may also be due to the nature of the oxidizing system, although hypoiodous acid (HOI) is formed, the mediating oxidant is unknown.^{24,25}

Phenazine **6** was not formed when replacing HI (0.2 equiv) with HCl (0.2 equiv) (Scheme 4(a)). Under these conditions mainly recovered **4a** was observed with 4-chloro-3,6-dimethoxy-2-(morpholin-4-yl)aniline (**4f**) formed in 17% yield. The regioselectivity of the chlorination was confirmed by X-ray crystallography (Scheme 4(b) and Figure S1). The yield of chlorinated aniline **4f** increased to 76% through use of a stoichiometric equivalent of HCl with H₂O₂. The greater reactivity of catalytic amounts of HI relative to HCl, reflects the lower p*K*_a of HI,²⁶ and relative ease of oxidation of iodine,²⁷ which allows facile breakdown of H₂O₂.^{24,25}

Table 1. Yields Obtained from H₂O₂ and HI-Mediated Reactions.^a


Entry	Aniline	Y	n	HI (mmol)	Time (h)	Yield of 5a-5e (%) ^b	Yield of 6 (%) ^{b, c}
1	4a	0	1	0.0	16	5a, 0	0
2	4a	0	1	1.0	1	5a, 56	25
3	4a	0	1	0.2	1	5a, 69	19
4	4b		1	0.2	1	5b, 74	11
5	4c	CH ₂	1	0.2	1	5c, 72	12
6	4d	CH ₂	0	0.2	1	5d, 89	0
7	4e	CH ₂	2	0.2	1	5e, 91	0
8	4a	0	1	0.2 ^d	1	5a, 28	47
9	4a	0	1	0.2 ^{d, e}	16	5a, 4	79
10	4a	0	1	0.2 ^{d, f}	24	5a, 2	82

^aConditions: Aniline (1.0 mmol), H₂O₂ (20.0 mmol), EtOAc (40 mL). ^bIsolated. ^cPrecipitate. ^dEtOAc (10 mL). ^e40 °C. ^frt.

Scheme 3. Wohl-Aue Reaction.^a


^aConditions: (i) KOH (90 mmol), benzene (50 mL), reflux, 5 h.²²
(ii) *t*-BuOK (40 mmol), toluene (50 mL), reflux, 16 h.

Recently, chlorine (50 equiv) and bromine (50 equiv) with water (100 equiv) have been established as mediators for six-electron oxidation, converting 3,6-dimethoxy-2-(cycloamino)anilines into cyclized benzimidazolequinones (Scheme 1(b)).¹⁵ Molecular iodine is however, a less powerful oxidizing agent,²⁷ and using the latter conditions did not give benzimidazolequinones, but mixtures of difficult to separate iodinated aromatics. In the iodine-mediated reactions, ethyl acetate was replaced by acetonitrile, since the former solvent is immiscible with water. Using iodine (10 equiv) in 20% aqueous acetonitrile, a 4-electron oxidation occurred in 10 minutes to give cyclized non-iodinated benzimidazoles (Scheme 4(c)). Morpholine **4a** and pyrrole **4d** were converted to 6,9-dimethoxy[1,4]oxazino[4,3-*a*]benzimidazole (**5a**) and 5,8-dimethoxypyrrolo[1,2-*a*]benzimidazole (**5d**) in 48% and 92% yield respectively. Similar to the H₂O₂ and HI-mediated reaction, the five-membered cyclization was regioselective, and did not give phenazine, however the less favored morpholine cyclization gave side-products, including **6** in 6% yield. Presumably for iodine in water, the concentration of HOI is greater than in the H₂O₂ and HI-mediated reactions (in Table 1) resulting in intractable iodinated side-products.

Scheme 4. Alternative Oxidative Conditions and X-ray Crystal Structure with Cyclization of 4-Chloro-3,6-dimethoxy-2-(morpholin-4-yl)aniline (4f**) (Thermal Ellipsoids Set at 40% Probability).**

^a& an intractable mixture of iodinated benzimidazoles.


Scheme 5. Proposed Mechanisms for the H₂O₂ and HI (Catalyst) Mediated Transformations Using 3,6-Dimethoxy-2-(morpholin-4-yl)aniline (4a).



Common to the oxidative cyclization of *o*-cyclic amine substituted anilines to give benzimidazoles,^{10,28} and the Wohl-Aue and other phenazine syntheses,^{19,20,29} is the likelihood of a nitroso-intermediate. Transformations via the *N*-oxide of the *tert*-amine of 4a are unlikely, with amine *N*-oxides isolated intermediates only when the primary NH₂ is deactivated to an acetamide.^{30,31} We were however unable to isolate a nitroso-intermediate, although encouragingly GC-MS of the reaction mixture (entry 10, Table 1) after 1 hour revealed an EI-MS fragmentation pattern supporting the formation of intermediate 7 (Figure S2, Scheme 5). The existence of highly reactive nitroso-intermediate 7 is supported by Meth-Cohn, who also refuted claims of isolations of *o*-nitroso-*tert*-anilines, including the nitrosation of *p*-benzyl dimethylaniline, which gave only the nitro-compound.³² Nitroso 7 should undergo a formal 1,5-hydride shift to the likely hydroxylamine 8,^{28,32-34} which subsequently cyclizes and is oxidized to give benzimidazole 5a. The unexpected 1,4,6,9-tetramethoxyphenazine (6) formation via nitroso intermediate 7 would involve intermolecular reaction of 7 with starting aniline 4a resulting in nucleophilic aromatic substitution adduct 10. The proposed formation of iodide 11 is reminiscent of the Bamberger-Ham reaction for making phenazine-*N*-oxides,³⁵ where two nitrosobenzenes substituted with *para*-electron-donating (through resonance) groups condense under acidic conditions.^{19,20} It is known that HOI reacts with H₂O₂ via a reduction to generate additional HI,^{24,25} which would favor conversion of 10 to 11. Further the yield of phenazine 6 is increased when using a full equivalent of HI (entry 2, Table 1). Similar to the conversion of hydroxylamine salts 9 and 11 into products 5a and 6 respectively, Nguyen et al. also proposed iodide as a direct reductant for removal of oxygen in iodine-catalyzed reductive cyclizations of *o*-nitro-*tert*-anilines to give benzimidazoles.³³ The necessity for the electron-donating (OMe) group in our H₂O₂ and HI-mediated synthesis of phenazine was investigated using 2-(morpholin-4-yl)aniline (12a)¹³ and 2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (12b), prepared from 1-fluoro-2-nitrobenzene (Scheme 6). In both cases, oxidative cyclization adducts (13a³³ and 13b) were exclusively isolated in moderate yields (67 and 70%) after column chromatography with

phenazine 14³⁶ not observed. The presence of appropriately positioned OMe groups does not however guarantee phenazine formation. Surprisingly chloride 4f exclusively cyclized to give 7-chloro-6,9-dimethoxy-3,4-dihydro-1*H*-[1,4]oxazino[4,3-*a*]benzimidazole (5f) in 79% isolated yield (Scheme 4(b)), using the H₂O₂ and HI reaction conditions (in Table 1), which favored formation of 6. Presumably electronic effects of the Cl substituent circumvent the S_NAr step (in Scheme 5).

Scheme 6. Preparation of 2-(2-Oxa-7-azaspiro[3.5]nonan-7-yl)aniline (12b) and Oxidative Cyclizations.




The structure of 6',9'-dimethoxy-1',2'-dihydro-4'*H*-spiro[oxetane-3,3'-pyrido[1,2-*a*]benzimidazole] (5b) was confirmed by X-ray crystallography prior to being subjected to oxidative demethylation (Scheme 7 and Figure S3). The hypervalent iodine reagent [bis(trifluoroacetoxy)iodo]benzene (PIFA) in water at room temperature is reported to convert *p*-dimethoxybenzenes to quinones.³⁷ This mild procedure was used to give target ether-containing ring-fused benzimidazolequinones 1 and 2 in 74% and 78% yield from 6,9-dimethoxy-3,4-dihydro-1*H*-[1,4]oxazino[4,3-*a*]benzimidazole (5a) and spirocyclic oxetane ring-fused benzimidazole (5b) respectively. Importantly, PIFA unlike other oxidants,^{38,39} had no

apparent adverse effect on the integrity of the oxetane motif.

In summary, H₂O₂ and HI-mediated oxidative cyclization of 3,6-dimethoxy-2-(cycloamino)anilines to give the ring-fused benzimidazoles can be tuned to alternatively give 1,4,6,9-tetramethoxyphenazine (**6**) in high yield. Phenazine formation is however not ubiquitous and competes with the six-membered cyclization only when the 3,6-dimethoxy-2-(cycloamino)anilines are suitably activated. The detection of nitroso-intermediate **7**, has led to a proposed mechanism for this new HI-catalyzed reaction. Future work will establish the anti-tumor activity and NQO1 specificity of the synthesized benzimidazolequinones.

Scheme 7. Oxidative Demethylation and X-ray Crystal Structure of 6',9'-Dimethoxy-1',2'-dihydro-4'H-spiro[oxetane-3,3'-pyrido[1,2-a]benzimidazole] (5b**) (Thermal Ellipsoids Set at 40% Probability).**



X-ray crystal structure of **5b**

Experimental Section

Materials

All chemicals were obtained from commercial sources and used without further purification. 1,4-Dimethoxy-2,3-dinitrobenzene was prepared from 1,4-dimethoxybenzene (Sigma Aldrich, 99% (GC)) and nitric acid (Honeywell Fluka, 64-66%).⁴⁰ Bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate was prepared using the procedure described by our group.¹⁷ The preparations of 3,6-dimethoxy-2-(morpholin-4-yl)aniline (**4a**), 3,6-dimethoxy-2-(piperidin-1-yl)aniline (**4c**), 3,6-dimethoxy-2-(pyrrolidin-1-yl)aniline (**4d**) and 2-(azepan-1-yl)-3,6-dimethoxyaniline (**4e**) were previously reported using the S_NAr of morpholine (Alfa Aesar, 99%), piperidine (Sigma Aldrich, 99%), pyrrolidine (Acros, >99%), and azepane (Fluorochem, >98%) respectively onto 1,4-dimethoxy-2,3-dinitrobenzene, followed by reduction with iron powder (Alfa Aesar, reduced, 99%).^{14,15} 2,5-Dimethoxyaniline was prepared by the reduction of 1,4-dimethoxy-2-nitrobenzene (TCI, >99.0% (GC)) using iron powder.⁴¹ 2-(Morpholin-4-yl)aniline (**12a**)¹³ was prepared by the S_NAr of morpholine

onto 1-fluoro-2-nitrobenzene (Fluorochem, 99%), followed by reduction with iron powder. H₂O₂ (Honeywell Fluka, 50% w/v in water, stabilized), HI (Sigma Aldrich, 57% w/v in water), HCl (Sigma Aldrich, 37% w/v in water), I₂ (VWR, ≥99%, resublimed), and PIFA (Sigma Aldrich, 97%) were used as received. Thin layer chromatography (TLC) was performed on TLC silica gel 60 F₂₅₄ plates. Flash column chromatography was carried out on silica gel (Apollo Scientific 60/40–63 μm).

Measurements

Melting points: Melting points were measured on a Stuart Scientific melting point apparatus SMP1, except for 1,4,6,9-tetramethoxyphenazine (**6**) recorded using differential scanning calorimetry (DSC) performed on a Mettler Toledo DSC822 differential scanning calorimeter, using standard aluminum pans.

Gas chromatography: GC-MS used to detect the formation of nitrosoarene **7** was performed on an Agilent 6890N Series GC system equipped with an Agilent 5973 Inert Mass Selective Detector (EI) and an SGE, 25 m, ID 0.25 mm, FD 0.25 μm column. The carrier gas used was He at a flow rate of 1.3 mL/min. The injector heated to 80 °C and the oven temperature increased from 80 to 280 °C at the rate of 10 °C/min and increased to 320 °C at 40 °C/min.

Infrared (IR) spectroscopy: IR spectra were recorded using a Perkin-Elmer Spec 1 with ATR attached.

Nuclear Magnetic Resonance (NMR) spectroscopy: NMR spectra for compounds **2**, **3**, **4b** and **5b** were recorded using a Jeol ECX 400 MHz instrument equipped with a DEC AXP 300 computer workstation. NMR Spectra for all other compounds were recorded using a Bruker Avance II 400 MHz spectrometer. The chemical shifts are in ppm relative to tetramethylsilane. ¹³C-NMR spectra at 100 MHz are with complete proton decoupling. NMR assignments are supported by Distortionless Enhancement by Polarization Transfer (DEPT) and ¹H-¹H and ¹H-¹³C correlation.

High resolution mass spectrometry (HRMS): HRMS spectra were obtained using ESI time-of-flight mass spectrometer (TOFMS) on a Waters LCT Mass Spectrometry instrument. The precision of all accurate mass measurements was better than 5 ppm.

X-ray crystallography: A single crystal of **4f** was grown from CH₂Cl₂ at 2 °C, and a single crystal of **5b** was grown by slow evaporation from CH₂Cl₂. Single crystal data was collected using an Oxford Diffraction Xcalibur system operated using the CrysAlisPro software and the data collection temperature was controlled at 298 K using a Cryojet system from Rigaku Oxford Diffraction. The crystal structures were solved using ShelxT version 2014/55,⁴² and refined using ShelxL version 2017/1,⁴³ both of which were operated within the Oscale software package.⁴⁴ Crystallographic data for compounds **4f** and **5b** was deposited with the Cambridge Crystallographic Data Centre with deposit number of CCDC 1917886 and CCDC 1917885 respectively. This data is available free of charge via www.ccdc.cam.ac.uk/data_request/cif (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax +44 1223 336033; or e-mail deposit@ccdc.cam.ac.uk).

Experimental Procedures

Synthesis of 3,6-Dimethoxy-2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (4b). 1,4-Dimethoxy-2,3-dinitrobenzene (0.680 g, 2.98 mmol), bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate (2.053 g, 5.96 mmol) and K₂CO₃ (1.647 g, 11.92 mmol) in MeCN (30 mL) and H₂O (6 mL) were heated at reflux for 40 h. The mixture was evaporated, dissolved in EtOAc (30 mL) and washed with brine (3 x 20 mL). The organic extract was dried (MgSO₄), evaporated, and purified by column chromatography using gradient elution of petroleum ether/EtOAc to give 7-(3,6-dimethoxy-2-nitrophenyl)-2-oxa-7-azaspiro[3.5]nonane (**3**) (0.624 g, 68%) as a yellow solid; *R*_f 0.44 (1:1 pet. ether/EtOAc); m.p. 125-127 °C; *v*_{max} (neat, cm⁻¹) 2931, 2861, 2841, 1539 (NO₂), 1495, 1381 (NO₂), 1256, 1094, 1057; ¹H NMR (400 MHz, CDCl₃) δ: 6.83 (d, *J* = 9.2 Hz, 1H), 6.74 (d, *J* = 9.2 Hz, 1H), 4.42 (s, 4H, OCH₂), 3.80 (s, 3H, Me), 3.78 (s, 3H, Me), 2.97-2.90 (br.s, 4H), 1.88-1.80 (br.s, 4H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 152.7, 144.5, 141.9, 133.9 (all C), 112.9, 109.4 (both CH), 82.1 (OCH₂), 56.8, 56.2 (both Me), 47.8 (CH₂), 38.4 (C), 35.6 (CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₅H₂₁N₂O₅ 309.1449; Found 309.1450.

Nitrobenzene **3** (0.616 g, 2.00 mmol), iron powder (0.357 g, 6.40 mmol) and NH₄Cl (55 mg, 1.00 mmol) in EtOH (40 mL) and H₂O (12 mL) were heated at reflux for 18 h. The mixture was filtered through Celite[®], evaporated, dissolved in EtOAc (80 mL) and washed with brine (2 x 60 mL). The organic extract was dried (MgSO₄), evaporated, and purified by column chromatography using gradient elution of petroleum ether/EtOAc to give **4b** (0.445 g, 80%) as an off-white solid; *R*_f 0.33 (3:1 pet. ether/EtOAc); m.p. 138-140 °C; *v*_{max} (neat, cm⁻¹) 3444, 3338, 2989, 2917, 2856, 2830, 1605, 1556, 1490, 1258, 1107; ¹H NMR (400 MHz, CDCl₃) δ: 6.54 (d, *J* = 8.8 Hz, 1H), 6.13 (d, *J* = 8.8 Hz, 1H), 4.56 (s, 2H, OCH₂), 4.40 (s, 2H, OCH₂), 4.37-4.27 (br.s, disappears with D₂O, 2H, NH₂), 3.78 (s, 3H, Me), 3.71 (s, 3H, Me), 3.14 (t, *J* = 12.1 Hz, 2H), 2.75 (d, *J* = 11.4 Hz, 2H), 2.13 (d, *J* = 12.4 Hz, 2H), 1.79-1.66 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 153.6, 142.1, 135.4, 126.3 (all C), 107.5, 99.0 (both CH), 82.8, 81.7 (both OCH₂), 56.1, 55.5 (both Me), 47.3 (CH₂), 38.6 (C), 36.7 (CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₅H₂₃N₂O₃ 279.1709; Found 279.1701.

Synthesis of 2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (12b). 1-Fluoro-2-nitrobenzene (0.296 g, 2.10 mmol), bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate (0.722 g, 2.10 mmol) and K₂CO₃ (1.161 g, 8.40 mmol) in MeCN (20 mL) and H₂O (4 mL) were heated at reflux for 5 h. The mixture was evaporated, dissolved in EtOAc (20 mL) and washed with brine (3 x 20 mL). The organic extract was dried (MgSO₄), evaporated, and purified by column chromatography using gradient elution of petroleum ether/EtOAc to give 7-(2-nitrophenyl)-2-oxa-7-azaspiro[3.5]nonane (0.489 g, 94%) as an orange solid; *R*_f 0.38 (3:2 pet. ether/EtOAc); m.p. 95-96 °C; *v*_{max} (neat, cm⁻¹) 2931, 2859, 2814, 1603, 1567, 1519 (NO₂), 1488, 1463, 1444, 1384, 1343 (NO₂), 1298, 1234, 1167, 1129; ¹H NMR (400 MHz, CDCl₃) δ: 7.76 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.48-7.43 (m, 1H), 7.11 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.05-7.00 (m, 1H), 4.48 (s, 4H, OCH₂), 2.95 (t, *J* = 5.5 Hz, 4H), 2.02 (t, *J* = 5.5 Hz, 4H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 146.3, 143.3 (both C), 133.4, 125.9, 121.7, 121.2 (all CH), 81.6 (OCH₂), 49.2 (CH₂),

38.3 (C), 34.9 (CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₃H₁₇N₂O₃ 249.1239; Found 249.1245.

The above nitrobenzene (0.480 g, 1.94 mmol), iron powder (0.347 g, 6.21 mmol) and NH₄Cl (52 mg, 0.97 mmol) in EtOH (30 mL) and H₂O (10 mL) were heated at reflux for 16 h. The mixture was filtered through Celite[®], evaporated, dissolved in EtOAc (60 mL) and washed with brine (2 x 40 mL). The organic extract was dried (MgSO₄), evaporated, and purified by column chromatography using gradient elution of petroleum ether/EtOAc to give **12b** (0.372 g, 88%) as a pale brown solid; *R*_f 0.35 (3:2 pet. ether/EtOAc); m.p. 137-139 °C; *v*_{max} (neat, cm⁻¹) 3408, 3325, 3032, 2914, 2856, 2806, 2740, 2677, 1617, 1501, 1461, 1438, 1425, 1383, 1289, 1211, 1135, 1125; ¹H NMR (400 MHz, CDCl₃) δ: 6.94-6.86 (m, 2H), 6.74-6.65 (m, 2H), 4.46 (s, 4H, OCH₂), 4.02-3.87 (br.s, disappears with D₂O, 2H, NH₂), 2.89-2.60 (br.s, 4H), 2.06-1.86 (br.s, 4H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 141.6, 139.6 (both C), 124.6, 119.8, 118.5, 115.1 (all CH), 81.9 (OCH₂), 48.7 (CH₂), 38.6 (C), 35.9 (CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₃H₁₉N₂O 219.1497; Found 219.1487.

H₂O₂ and HX-Mediated Transformations

Reaction conditions are given in Table 1 and Schemes 4(b), and 6 for H₂O₂ and HI, and in Scheme 4(a) for H₂O₂ and HCl. H₂O₂ and HX were sequentially added dropwise to a stirred solution of the anilines (1 mmol) in EtOAc (10 or 40 mL) at the indicated reaction temperatures. For the room temperature reaction of aniline **4a**, the addition of H₂O₂ and HI were done over ice, and the mixture was then allowed to warm to room temperature. At the end of the reaction, the solution was filtered, and the orange precipitate washed with EtOAc (30 mL) to give 1,4,6,9-tetramethoxyphenazine (**6**). The filtrate was washed with Na₂CO₃ (satd., 60 mL), and dried (MgSO₄). The organic extract was evaporated, and the residue triturated from Et₂O to give benzimidazoles **5a-5d**. Azepane **5e** did not require purification. The residues of **4f**, **5f**, **13a** and **13b** were purified by column chromatography using gradient elution of petroleum ether/EtOAc.

6,9-Dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole (5a) (0.161 g, 69%, Table 1, entry 3); pale brown solid; m.p. 109-111 °C; *v*_{max} (neat, cm⁻¹) 2929, 2827, 1523, 1475, 1440, 1426, 1402, 1316, 1259, 1227, 1193, 1165, 1119, 1103, 1084; ¹H NMR (400 MHz, CDCl₃) δ: 6.45 (AB_q, *J* = 8.6 Hz, 2H), 4.92 (s, 2H, 1-CH₂), 4.41 (t, *J* = 5.2 Hz, 2H), 4.03 (t, *J* = 5.2 Hz, 2H), 3.87 (s, 3H, Me), 3.79 (s, 3H, Me); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 146.3, 145.8, 141.8, 134.4, 125.0 (all C), 102.8, 102.0 (both CH), 65.5 (1-CH₂), 64.3 (CH₂), 55.9, 55.8 (both Me), 44.9 (CH₂); HRMS (ESI) *m/z* [M+H]⁺ Calcd for C₁₂H₁₅N₂O₃ 235.1083; Found 235.1081, and 1,4,6,9-tetramethoxyphenazine (**6**) (29 mg, 19%); orange solid; m.p. (DSC) onset 351.2 °C, peak max 355.9 °C (lit m.p.²⁶ >360 °C); *v*_{max} (neat, cm⁻¹) 3075, 3010, 2900, 2833, 1177, 1622, 1492, 1456, 1445, 1437, 1322, 1266, 1248, 1197, 1157, 1127, 1109; ¹H NMR (400 MHz, CDCl₃) δ: 6.97 (s, 4H), 4.09 (s, 12H, Me); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 148.8, 135.6 (both C), 106.0 (CH), 56.1 (Me); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₆H₁₇N₂O₄ 301.1188; Found 301.1179.

6',9'-Dimethoxy-1',2'-dihydro-4'H-spiro[oxetane-3,3'-pyrido-[1,2-a]benzimidazole] (5b) (0.203 g, 74%); off-white solid; m.p. 166-167 °C; *v*_{max} (neat, cm⁻¹) 3004, 2931, 2865, 2837, 1810, 1606, 1523, 1441, 1260, 1223, 1100, 1082; ¹H NMR

(400 MHz, CDCl₃) δ: 6.47 (s, 2H), 4.53 (AB_q, *J* = 6.1 Hz, 4H, OCH₂), 4.45 (t, *J* = 6.3 Hz, 2H, 1'-CH₂), 3.92 (s, 3H, Me), 3.83 (s, 3H, Me), 3.32 (s, 2H, 4'-CH₂), 2.34 (t, *J* = 6.3 Hz, 2H, 2'-CH₂); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 148.2, 145.6, 141.8, 135.0, 125.3 (all C), 102.6, 101.8 (both CH), 80.8 (OCH₂), 55.93, 55.89 (both Me), 41.7 (1'-CH₂), 37.7 (C), 35.0 (4'-CH₂), 31.3 (2'-CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₅H₁₉N₂O₃ 275.1396; Found 275.1380, and 1,4,6,9-tetramethoxyphenazine (**6**) (17 mg, 11%).

6,9-Dimethoxy-1,2,3,4-tetrahydropyrido[1,2-*a*]benzimidazole (**5c**) (0.167 g, 72%); brown solid; spectral data and melting point consistent with the literature,¹⁴ and 1,4,6,9-tetramethoxyphenazine (**6**) (18 mg, 12%).

5,8-Dimethoxy-2,3-dihydro-1H-pyrrolo[1,2-*a*]benzimidazole (**5d**) (0.194 g, 89%); off-white solid; spectral data and melting point consistent with the literature.¹⁴

1,4-Dimethoxy-7,8,9,10-tetrahydro-6H-azepino[1,2-*a*]benzimidazole (**5e**) (0.224 g, 91%); brown oil; spectral data consistent with the literature.¹⁴

4-Chloro-3,6-dimethoxy-2-(morpholin-4-yl)aniline (**4f**) (0.207 g, 76%); *R*_f 0.51 (1:1 pet. ether/EtOAc); pale brown solid; m.p. 149-151 °C; *v*_{max} (neat, cm⁻¹) 3434, 3335, 2960, 2909, 2881, 2843, 1596, 1549, 1480, 1456, 1445, 1419, 1261, 1177, 1153, 1041; ¹H NMR (400 MHz, CDCl₃) δ: 6.65 (s, 1H), 3.98-3.88 (br.s, 2H), 3.87 (s, 3H, Me), 3.81 (s, 3H, Me), 3.78-3.63 (br.s, 2H), 3.52-3.35 (br.s, 2H), 2.87-2.68 (br.s, 2H), NH₂ is absent; ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 148.9, 143.6, 133.7, 130.5, 114.8 (all C), 109.3 (CH), 68.4 (2 x CH₂), 61.8, 56.0, (both Me), 51.0 (2 x CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₂H₁₈N₂O₃Cl 273.1006; Found 273.1012; and 6,9-dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-*a*]benzimidazole (**5a**) (9 mg, 4%); *R*_f 0.35 (EtOAc).

7-Chloro-6,9-dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-*a*]benzimidazole (**5f**) (0.212 g, 79%); *R*_f 0.43 (EtOAc); brown solid; m.p. 144-146 °C; *v*_{max} (neat, cm⁻¹) 2931, 2836, 2359, 1605, 1508, 1473, 1428, 1399, 1309, 1212, 1153, 1111, 1070; ¹H NMR (400 MHz, CDCl₃) δ: 6.64 (s, 1H), 5.00 (s, 2H, 1-CH₂), 4.44 (t, *J* = 5.2 Hz, 2H), 4.17 (t, *J* = 5.2 Hz, 2H), 3.96 (s, 3H, Me), 3.94 (s, 3H, Me); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 147.7, 147.0, 136.7, 133.4, 128.5, 120.5 (all C), 104.8 (CH), 65.5, 64.1 (CH₂), 62.5, 56.1 (both Me), 44.2 (CH₂); HRMS (ESI) *m/z* [M + H]⁺ Calcd for C₁₂H₁₄N₂O₃Cl 269.0693; Found 269.0685.

3,4-Dihydro-1H-[1,4]oxazino[4,3-*a*]benzimidazole (**13a**) (0.117 g, 67%); pale brown solid; *R*_f 0.21 (EtOAc); spectral data and melting point consistent with the literature.³³

1',2'-dihydro-4'H-spiro[oxetane-3,3'-pyrido[1,2-*a*]benzimidazole] (**13b**) (0.149 g, 70%); off-white solid; *R*_f 0.23 (1:10 MeOH/EtOAc) m.p. 141-143 °C; *v*_{max} (neat, cm⁻¹) 3052, 2936, 2864, 1668, 1616, 1516, 1485, 1457, 1417, 1371, 1344, 1319, 1283, 1228, 1161; ¹H NMR (400 MHz, CDCl₃) δ: 7.73-7.67 (m, 1H), 7.33-7.28 (m, 1H), 7.28-7.22 (m, 2H), 4.59 (AB_q, *J* = 6.2 Hz, 4H, OCH₂), 4.14 (t, *J* = 6.3 Hz, 2H, 1'-CH₂), 3.40 (s, 2H, 4'-CH₂), 2.47 (t, *J* = 6.3 Hz, 2H, 2'-CH₂); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 149.5, 143.2, 134.3 (all C), 122.4, 122.2, 119.2, 108.9 (all CH), 80.6 (OCH₂), 38.8 (1'-CH₂), 38.0 (C), 34.9 (4'-CH₂), 30.7 (2'-CH₂); HRMS (ESI) *m/z* [M + H]⁺ C₁₃H₁₅N₂O Calcd for 215.1184; Found 215.1180.

Modified Wohl-Aue Reaction

Reaction conditions are given in Scheme 3. At the end of the reaction, the mixture was filtered, and the precipitate washed with water (30 mL) to give **6** (1.02 g, 34%) as an orange solid. Spectral data and melting point of phenazine **6** is consistent with the above.

Aqueous I₂-mediated transformations

Anilines (1.00 mmol) in MeCN (10 mL) and H₂O (2 mL) were heated to reflux. I₂ (10.00 mmol) was added, and the mixture was stirred at reflux for 10 min. The mixture was filtered, and the precipitate washed with water (20 mL) to give phenazine **6**. The filtrate was washed with Na₂CO₃ (satd., 20 mL) and Na₂S₂O₃ (1 M, 20 mL), and the organic extract was dried (MgSO₄) and evaporated to dryness. Benzimidazole **5d** did not require purification. The residue of benzimidazole **5a** was purified by column chromatography using gradient elution of petroleum ether/EtOAc.

6,9-Dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-*a*]benzimidazole (**5a**) (0.112 g, 48%), *R*_f 0.35 (EtOAc); and 1,4,6,9-tetramethoxyphenazine (**6**) (9 mg, 6%). Spectral data and melting points for **5a** and **6** were consistent with the above.

5,8-Dimethoxy-2,3-dihydro-1H-pyrrolo[1,2-*a*]benzimidazole (**5d**) (0.201 g, 92%); off-white solid; spectral data and melting point consistent with the literature.¹⁴

General Procedure for the Synthesis of Quinones 1 and 2.

Benzimidazole (0.26 mmol) and PIFA (0.447 g, 1.04 mmol) in H₂O (29 mL) and MeOH (0.75 mL) were stirred at room temperature for 2 h. The mixture was extracted with CH₂Cl₂ (3 x 40 mL). The organic extracts were dried (MgSO₄), evaporated, and purified by column chromatography using gradient elution of petroleum ether/EtOAc and EtOAc/MeOH.

3,4-Dihydro-1H-[1,4]oxazino[4,3-*a*]benzimidazole-6,9-dione (**1**) (39 mg, 74%); yellow solid; *R*_f 0.41 (EtOAc); m.p. (decomp. >165 °C); *v*_{max} (neat, cm⁻¹) 2924, 1664 (C=O), 1584, 1531, 1475, 1436, 1379, 1345, 1317, 1289, 1225, 1202, 1112, 1095, 1066; ¹H NMR (400 MHz, CDCl₃) δ: 6.68 (AB_q, *J* = 10.4 Hz, 2H), 4.99 (s, 2H, 1-CH₂), 4.44 (t, *J* = 5.2 Hz, 2H), 4.14 (t, *J* = 5.2 Hz, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 180.9, 178.1 (both C=O), 148.0, 141.2 (both C), 136.6, 135.8 (both CH), 130.1 (C), 65.0 (1-CH₂), 63.3, 44.7 (both CH₂); HRMS (ESI) *m/z* [M + H]⁺ C₁₀H₉N₂O₃ Calcd for 205.0613; Found 205.0623.

1',2'-Dihydro-4'H-spiro[oxetane-3,3'-pyrido[1,2-*a*]benzimidazole]-6',9'-dione (**2**) (49 mg, 78%); yellow oil; *R*_f 0.44 (1:10 MeOH/EtOAc); *v*_{max} (neat, cm⁻¹) 2929, 1661 (C=O), 1510, 1487, 1446, 1350, 1270, 1202, 1132; ¹H NMR (400 MHz, CDCl₃) δ: 6.62 (AB_q, *J* = 10.4 Hz, 2H), 4.56 (AB_q, *J* = 6.2 Hz, 4H, OCH₂), 4.38 (t, *J* = 6.2 Hz, 2H, 1'-CH₂), 3.32 (s, 2H, 4'-CH₂), 2.38 (t, *J* = 6.2 Hz, 2H, 2'-CH₂); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ: 181.1, 178.2 (both C=O), 151.9, 149.9 (both C), 136.5, 136.0 (both CH), 130.2 (C), 80.5 (OCH₂), 41.7 (1'-CH₂), 37.2 (C), 34.4 (4'-CH₂), 30.4 (2'-CH₂); HRMS (ESI) *m/z* [M + H]⁺ C₁₃H₁₃N₂O₃ Calcd for 245.0926; Found 245.0923.

ASSOCIATED CONTENT

Supporting Information. The supporting information is

available free of charge via <http://pubs.acs.org> at DOI: XXXXXXXX.
GC-MS, ¹H and ¹³C NMR spectra, and crystallographic data (PDF).

AUTHOR INFORMATION

Corresponding Author

* E-mail: f.aldabbagh@kingston.ac.uk

Present Addresses

§ Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, Penrhyn Road, Kingston upon Thames, KT1 2EE, UK.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

We thank Kingston University for a PhD studentship for Darren Conboy, and the Irish Research Council (IRC) for a Government of Ireland Postdoctoral Fellowship for Styliana I. Mirallai.

REFERENCES

- (1) Vitaku, E.; Smith, D. T.; Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274.
- (2) St. Jean Jr., D. J.; Fotsch, C. Mitigating Heterocycle Metabolism in Drug Discovery. *J. Med. Chem.* **2012**, *55*, 6002–6020.
- (3) Arshad, F.; Khan, M. F.; Akhtar, W.; Alam, M. M.; Nainwal, L. M.; Kaushik, S. K.; Akhter, M.; Parvez, S.; Hasan, S. M.; Shaquiquzzaman, M. Revealing Quinquennial Anticancer Journey of Morpholine: A SAR Based Review. *Eur. J. Med. Chem.* **2019**, *167*, 324–356.
- (4) Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in Drug Discovery: Structural and Synthetic Insights. *J. Med. Chem.* **2010**, *53*, 3227–3246.
- (5) Bull, J. A.; Croft, R. A.; Davis, O. A.; Doran, R.; Morgan, K. F. Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry. *Chem. Rev.* **2016**, *116*, 12150–12233.
- (6) Zhang, K.; Chen, D.; Ma, K.; Wu, X.; Hao, H.; Jiang, S. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. *J. Med. Chem.* **2018**, *61*, 6983–7003.
- (7) Colucci, M. A.; Couch, G. D.; Moody, C. J. Natural and Synthetic Quinones and their Reduction by the Quinone Reductase Enzyme NQO1: From Synthetic Organic Chemistry to Compounds with Anticancer Potential. *Org. Biomol. Chem.* **2008**, *6*, 637–656.
- (8) Newsome, J. J.; Colucci, M. A.; Hassani, M.; Beall, H. D.; Moody, C. J. Benzimidazole- and Benzothiazole-

Quinones: Excellent Substrates for NAD(P)H:Quinone Oxidoreductase 1. *Org. Biomol. Chem.* **2007**, *5*, 3665–3673.

(9) Fagan, V.; Bonham, S.; Carty, M. P.; Saenz-Méndez, P.; Eriksson, L. A.; Aldabbagh, F. COMPARE Analysis of the Toxicity of an Iminoquinone Derivative of the Imidazo[5,4-*f*]benzimidazoles with NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Activity and Computational Docking of Quinones as NQO1 Substrates. *Bioorg. Med. Chem.* **2012**, *20*, 3223–3232.

(10) Nair, M. D.; Adams, R. Benzimidazole Syntheses by Oxidative Cyclization with Peroxytrifluoroacetic Acid. *J. Am. Chem. Soc.* **1961**, *83*, 3518–3521.

(11) Meth-Cohn, O.; Smalley R. K.; Suschitzky, H. Syntheses of Heterocyclic Compounds. Part III. Pyrolytic Cyclisation of Aromatic Azides. *J. Chem. Soc.* **1963**, 1666–1669.

(12) Fahey, K.; Aldabbagh, F. Synthesis of Seven- and Eight-Membered [1,2-*a*] Alicyclic Ring-Fused Benzimidazoles and 3-Aziridinylazepino[1,2-*a*]benzimidazolequinone as a Potential Antitumour Agent. *Tetrahedron Lett.* **2008**, *49*, 5235–5237.

(13) Gurry, M.; Sweeney, M.; McArdle, P.; Aldabbagh, F. One-Pot Hydrogen Peroxide and Hydrohalic Acid Induced Ring Closure and Selective Aromatic Halogenation To Give New Ring-Fused Benzimidazoles. *Org. Lett.* **2015**, *17*, 2856–2859.

(14) Sweeney, M.; Gurry, M.; Keane, L.-A. J.; Aldabbagh, F. Greener Synthesis Using Hydrogen Peroxide in Ethyl Acetate of Alicyclic Ring-Fused Benzimidazoles and Anti-Tumour Benzimidazolequinones. *Tetrahedron Lett.* **2017**, *58*, 3565–3567.

(15) Sweeney, M.; Keane, L.-A. J.; Gurry, M.; McArdle, P.; Aldabbagh, F. One-Pot Synthesis of Dihalogenated Ring-Fused Benzimidazolequinones from 3,6-Dimethoxy-2-(cycloamino)anilines Using Hydrogen Peroxide and Hydrohalic Acid. *Org. Lett.* **2018**, *20*, 6970–6974.

(16) Parr, R. G.; Szentpály, L. v.; Liu, S. Electrophilicity Index. *J. Am. Chem. Soc.* **1999**, *121*, 1922–1924.

(17) Gurry, M.; McArdle, P.; Aldabbagh, F. Synthesis of a Spirocyclic Oxetane-Fused Benzimidazole. *Molecules* **2015**, *20*, 13864–13874.

(18) Alder, C. M.; Hayler, J. D.; Henderson, R. K.; Redman, A. M.; Shukla, L.; Shuster, L. E.; Sneddon, H. F. Updating and Further Expanding GSK's Solvent Sustainability Guide. *Green Chem.* **2016**, *18*, 3879–3890.

(19) Laursen, J. B.; Nielsen, J. Phenazine Natural Products: Biosynthesis, Synthetic Analogues, and Biological Activity. *Chem. Rev.* **2004**, *104*, 1663–1686.

(20) Guttenberger, N.; Blankenfeldt, W.; Breinbauer, R. Recent Developments in the Isolation, Biological Function, Biosynthesis, and Synthesis of Phenazine Natural Products. *Bioorg. Med. Chem.* **2017**, *25*, 6149–6166.

(21) Wohl, A.; Aue, W. Ueber die Einwirkung von

Nitrobenzol auf Anilin bei Gegenwart von Alkali. *Ber. Dtsch. Chem. Ges.* **1901**, *34*, 2442–2450.

(22) Sugimoto, A.; Kato, S.; Inoue, H.; Imoto, E. Studies on Organic Semiconductors. XVIII. Photoconductivity of Heteroaromatic Compounds and Their Substituted Derivatives. *Bull. Chem. Soc. Jpn.* **1976**, *49*, 337–338.

(23) Wróbel, Z.; Stachowska, K.; Kwast, A. Phenazines and Their *N*-Oxides as Products of Cyclization of *N*-Aryl-2-nitrosoanilines – Disproof of the Reported Homolytic Cross-Coupling Process Leading to Benzo[*c*]cinnoline Oxides. *Eur. J. Org. Chem.* **2014**, *2014*, 7721–7725.

(24) Bray, W. C.; Liebhafsky, H. A. Reactions Involving Hydrogen Peroxide, Iodine and Iodate Ion. I. Introduction. *J. Am. Chem. Soc.* **1931**, *53*, 38–44.

(25) Schmitz, G. Iodine Oxidation by Hydrogen Peroxide in Acidic Solutions, Bray-Liebhafsky Reaction and Other Related Reactions. *Phys. Chem. Chem. Phys.* **2010**, *12*, 6605–6615.

(26) Trummal, A.; Lipping, L.; Kaljurand, I.; Koppel, I. A.; Leito, I. Acidity of Strong Acids in Water and Dimethyl Sulfoxide. *J. Phys. Chem. A* **2016**, *120*, 3663–3669.

(27) Isse, A. A.; Lin, C. Y.; Coote, M. L.; Gennaro, A. Estimation of Standard Reduction Potentials of Halogen Atoms and Alkyl Halides. *J. Phys. Chem. B* **2011**, *115*, 678–684.

(28) Purkait, A.; Roy, S. K.; Srivastava, H. K.; Jana, C. K. Metal-Free Sequential C(sp²)-H/OH and C(sp³)-H Aminations of Nitrosoarenes and *N*-Heterocycles to Ring-Fused Imidazoles. *Org. Lett.* **2017**, *19*, 2540–2543.

(29) Kwast, A.; Stachowska, K.; Trawczyński, A.; Wróbel, Z. *N*-Aryl-2-Nitrosoanilines as Intermediates in the Synthesis of Substituted Phenazines from Nitroarenes. *Tetrahedron Lett.* **2011**, *52*, 6484–6488.

(30) Fagan, V.; Bonham, S.; McArdle, P.; Carty, M. P.; Aldabbagh, F. Synthesis and Toxicity of New Ring-Fused Imidazo[5,4-*f*]benzimidazolequinones and Mechanism Using Amine *N*-Oxide Cyclizations. *Eur. J. Org. Chem.* **2012**, *2012*, 1967–1975.

(31) Meth-Cohn, O. Mechanism of Formation of Benzimidazoles by Oxidation of *o*-Acylamino-*NN*-Dialkylanilines with Peroxy-Acids. *J. Chem. Soc. C* **1971**, 1356–1357.

(32) Meth-Cohn, O. The *t*-Amino Effect: Heterocycles Formed by Ring Closure of *ortho*-Substituted *t*-Anilines. In *Adv. Heterocycl. Chem.*; A. R. Katritzky, Ed.; Academic Press: San Diego, CA, **1996**; Vol. 65, pp. 1–37.

(33) Nguyen, T. B.; Ermolenko, L.; Al-Mourabit, A. Formic Acid as a Sustainable and Complementary Reductant: An Approach to Fused Benzimidazoles by Molecular Iodine-Catalyzed Reductive Redox Cyclization of *o*-Nitro-*t*-anilines. *Green Chem.* **2016**, *18*, 2966–2970.

(34) Ogata, Y.; Sawaki, Y.; Mibae, J.; Morimoto, T. Kinetics of the Autoxidation of Phenylhydroxylamines to Azoxybenzenes in Methanol. *J. Am. Chem. Soc.* **1964**, *86*, 3854–3858.

(35) Bamberger, E.; Ham, W. Über das Verhalten einiger parasubstituierter Nitrosobenzole gegen konz. Schwefelsäure. *Ann. Chem.* **1911**, *382*, 82–128.

(36) Seth, K.; Raha Roy, S.; Chakraborti, A. K. Synchronous Double C–N Bond Formation via C–H Activation for a Novel Synthetic Route to Phenazine. *Chem. Commun.* **2016**, *52*, 922–925.

(37) Tohma, H.; Morioka, H.; Harayama, Y.; Hashizume, M.; Kita, Y. Novel and Efficient Synthesis of *p*-Quinones in Water via Oxidative Demethylation of Phenol Ethers using Hypervalent Iodine(III) Reagents. *Tetrahedron Lett.* **2001**, *42*, 6899–6902.

(38) Nair, V.; Rajan, R.; Mohanan, K.; Sheeba, V. Cerium(IV) Ammonium Nitrate-Mediated Oxidative Rearrangement of Cyclobutanes and Oxetanes. *Tetrahedron Lett.* **2003**, *44*, 4585–4588.

(39) Loman, J. J.; Carnaghan, E. R.; Hamlin, T. A.; Ovia, J. M.; Kelly, C. B.; Mercadante, M. A.; Leadbeater, N. E. A Combined Computational and Experimental Investigation of the Oxidative Ring-Opening of Cyclic Ethers by Oxoammonium Cations. *Org. Biomol. Chem.* **2016**, *14*, 3883–3888.

(40) Hammershøj, P.; Reenberg, T. K.; Pittelkow, M.; Nielsen, C. B.; Hammerich, O.; Christensen, J. B. Synthesis and Properties of 2,3-Dialkynyl-1,4-benzoquinones. *Eur. J. Org. Chem.* **2006**, *2006*, 2786–2794.

(41) Wang, G.-T.; Zhao, X.; Li, Z.-T. Hydrogen Bonded Arylamide-Linked Cholesteryl Dimesogenic Liquid Crystals: A Study of the Length and Side Chain Effects. *Tetrahedron* **2011**, *67*, 48–57.

(42) Sheldrick, G. M. SHELXT - Integrated Space-Group and Crystal-Structure Determination. *Acta Crystallogr. Sect. A: Found. Adv.* **2015**, *71*, 3–8.

(43) Sheldrick, G. M. Crystal Structure Refinement with SHELXL. *Acta Crystallogr. Sect. C: Struct. Chem.* **2015**, *71*, 3–8.

(44) McArdle, P. Oscail, a Program Package for Small-Molecule Single-Crystal Crystallography with Crystal Morphology Prediction and Molecular Modelling. *J. Appl. Crystallogr.* **2017**, *50*, 320–326.

Table of Contents artwork

